Office of Research
Clinical Trials

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA SCC of the Head and Neck

This is a phase II study evaluating the disease-free survival (DFS) of patients with stage III-IV squamous cell carcinoma of the head and neck (SCCHN) and disruptive p53 mutations after primary surgical resection followed by postoperative radiotherapy (PORT) alone or PORT with concurrent cisplatin. Participants in Arm A will undergo IMRT 5 days a week for 6 weeks, and those in Arm B will receive the same RT plus weekly Cisplatin via IV.

This study may be appropriate for those with: Newly Diagnosed Cancer

Pasritamig With Docetaxel Study

This phase 3 trial tests whether adding pasritamig to standard chemotherapy (docetaxel) helps men with metastatic castration resistant prostate cancer live longer without their disease getting worse on scans. Eligible men must have prostate adenocarcinoma that has spread, be on hormone lowering treatment or surgically castrated, have had at least one prior androgen receptor targeted therapy, and be in generally good health for cancer treatment. Participants are randomly assigned to receive pasritamig plus docetaxel or docetaxel alone. Doctors will use imaging scans to track when the cancer progresses, and will also measure overall survival, pain and quality of life, PSA blood changes, need for more treatment, bone related problems, tumor response if measurable, and side effects. Blood tests, scans, and questionnaires are used during treatment and for follow up. The main question is whether the combination delays radiographic progression compared with chemotherapy alone.

This study may be appropriate for those with: Metastatic Cancer

Study of CDK4/6 Inhibitor Dosing in Older Metastatic Breast Cancer Patients

This study seeks to help older patients (65 years and above) with metastatic breast cancer by testing different dosing strategies for CDK4/6 inhibitors. It aims to determine if starting these medications at a lower dose and increasing as tolerated could help patients manage side effects better, enabling them to continue their treatment longer. Participants can choose between the drugs palbociclib or ribociclib and an endocrine therapy, with dosing randomly assigned to either start at full dose (common practice) or begin at a lower dose and increase if tolerated. The trial will track the length of time patients stay on their medication, the side effects experienced, and overall survival and quality of life.

This study may be appropriate for those with: Metastatic Cancer

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations. Participants will choose to undergo surgery to remove the fallopian tubes only and plan to have the ovaries removed in the future (BLS group) or remove the fallopian tubes and ovaries at the same time (BSO group).

This study may be appropriate for those with: Newly Diagnosed Cancer

Blood Test for ctDNA in Guiding Immunotherapy After Bladder Cancer Surgery

This study investigates whether a blood test can detect leftover cancer after bladder surgery and guide further treatment using immunotherapy. It aims to identify patients who might need additional treatment to prevent cancer from coming back. The study uses blood tests to look for circulating tumor DNA (ctDNA), which can indicate cancer presence. Patients testing positive for ctDNA might receive immunotherapy drugs nivolumab and relatlimab, while those who test negative might not get additional treatment immediately. This research hopes to improve survival rates and quality of life for bladder cancer patients by tailoring immunotherapy based on ctDNA results.

This study may be appropriate for those with: Newly Diagnosed Cancer

DISP 10 Advanced GI Cancer Study

This is an early phase (Phase 1) study testing DISP 10, a combination of an engineered adenovirus (DV-10) and a CAR T cell therapy (idecabtagene vicleucel or ide‑cel). Adults with advanced or metastatic cancers of the esophagus, gastroesophageal junction, stomach, or colon who have measurable disease and at least one site for biopsy may join. The study has two parts: Part 1 slowly increases doses to find a recommended dose for expansion, focusing on safety and dose‑limiting toxicities. Part 2 treats more participants at that dose to learn about safety and whether tumors shrink or stabilize. Main goals are to record side effects, establish a safe dose, and measure tumor response. Participants must have good organ function and no major infections, recent transplants, or prior similar viral or CAR T therapies. Follow up includes frequent checks after treatment and ongoing monitoring for up to 2 years, with long term survival follow up possible up to 15 years.

This study may be appropriate for those with: Metastatic Cancer

Testing a New Combination Therapy for Advanced Lung Cancer

This study is looking at a new treatment combination for people with advanced lung cancer who have stopped responding to typical immune checkpoint inhibitors. The new combination includes the drugs N-803, tislelizumab, and docetaxel vs. just docetaxel alone, to see which is more effective in extending patients' lives. Adults 18 or older with this specific type of cancer could participate if they meet certain health requirements. Key aspects include the ability to follow the study procedures, managing contraception requirements, and having a specific level of health for various bodily functions. Some individuals will not qualify if they have recent treatments that conflict with the new drugs, have severe allergies to study drugs, or other significant health concerns.

This study may be appropriate for those with: Metastatic Cancer

ZEN003694 with Capecitabine for Advanced Solid Tumors

This phase I trial evaluates the safety, side effects, and optimal dosage of ZEN003694 combined with standard treatment capecitabine in patients with metastatic or unresectable solid tumors that have worsened after standard therapy. ZEN003694, a BET protein inhibitor, could inhibit tumor growth by targeting cells that produce excessive BET proteins. Capecitabine, an antimetabolite, converts into fluorouracil inside cancer cells to destroy them. The combination of ZEN003694 and capecitabine aims to safely treat these advanced cancers.

This study may be appropriate for those with: Metastatic Cancer

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

This is a randomized trial for patients diagnosed with Esophageal Cancer comparing Proton Beam Therapy and Intensity Modified Photon Radiotherapy. Patients randomized to Arm 1 will undergo Proton Beam therapy with concurrent weekly chemo with paclitaxel/carboplatin. Patients in Arm 2 will undergo IMRT with concurrent paclitaxel/carboplatin. The primary endpoint of this study is Overall Survival.

This study may be appropriate for those with: Newly Diagnosed Cancer

Teclistamab Maintenance Study

This is a Phase 3 clinical trial for people with newly diagnosed multiple myeloma who have completed initial therapy and are starting maintenance treatment after autologous stem cell transplant. Participants are randomly assigned to one of three maintenance options: teclistamab plus lenalidomide, teclistamab alone, or lenalidomide alone. The study will compare how long people live without their disease getting worse (progression-free survival) and how many achieve a deep response with no detectable disease at 12 months. Participants will be followed during treatment and for long-term outcomes, including overall survival, quality of life, and safety, for up to about 8 years. The goal is to find whether teclistamab, by itself or with lenalidomide, gives better and longer-lasting control of myeloma than standard lenalidomide alone.

This study may be appropriate for those with: Newly Diagnosed Cancer

Adding SNDX-5613 to the Standard Chemotherapy Treatment for Newly Diagnosed Patients With Acute Myeloid Leukemia

A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged Disease. This phase Ib trial evaluates the safety, side effects, and optimal dosage of SNDX-5613 in combination with standard chemotherapy (daunorubicin and cytarabine) for patients with newly diagnosed acute myeloid leukemia (AML) harboring NPM1 or MLL/KMT2A gene mutations. SNDX-5613 inhibits specific intracellular signaling pathways essential for the survival of cancer cells. Chemotherapy agents like daunorubicin and cytarabine work by various mechanisms to halt cancer cell proliferation, either by directly killing the cells, preventing their division, or inhibiting their spread. The hypothesis is that adding SNDX-5613 to conventional chemotherapy could potentially enhance cancer control, leading to longer periods of remission or stabilization compared to chemotherapy alone.

This study may be appropriate for those with: Newly Diagnosed Cancer

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

The purpose of this research is to study if a decrease in the dose of radiation to regions which have no visible cancer will be as effective as the standard dose. The dose to all visible cancer remains unchanged to the standard radiation approach. The researchers believe that a lower dose could be just as helpful for treating your cancer, while reducing the side effects of radiation and improving quality of life. The current standard care treatment for OPSCC can have debilitating side effects. The researchers believe that using a decreased dose of 30 Gy from 46-54 Gy to regions without visible cancer but which have a risk of microscopic cancer might be just as effective for treating your cancer with less side effects. The combination of these approaches is not considered the current standard of care and will be considered research. You will continue to receive standard systemic therapy of cisplatin during your radiation therapy.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study on UB-VV111 and Rapamycin for CD19+ B-cell Malignancies

This Phase 1 research involves the new drug UB-VV111, tested with or without another drug called Rapamycin, in people with specific B-cell cancers that have returned or don't respond to existing treatments. The goal is to understand if these treatments are safe and how well they work against cancer. Participants need to meet certain criteria, such as being 18 years or older, having specific types of relapsed or refractory B-cell lymphomas or leukemia, having no serious uncontrolled health conditions, and having good organ function. People can't participate if they are pregnant, have certain infections, or are part of another trial. Expected outcomes are monitored over a two-year timeframe.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Phase II Trial of Asciminib, Prednisone, Blinatumomab, for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia

This phase II study tests whether adding asciminib to a treatment plan of dasatinib, prednisone, and blinatumomab helps adults newly diagnosed with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Treatment has three parts: an induction phase to try to put the leukemia into remission, a post-remission consolidation phase with repeated 42-day cycles, and a maintenance phase where patients take oral drugs for up to five years if they benefit. Doctors will check response by measuring BCR-ABL levels in blood/marrow and by flow cytometry for measurable residual disease. Main goals are to see how many people reach a major molecular remission by about day 85 and to track remission rates, survival, and side effects over time. The study also collects samples to study genetic changes linked to response or resistance.

This study may be appropriate for those with: Newly Diagnosed Cancer

Efficacy and Safety of Adjuvant in Patients With Resected Pancreatic Ductal Adenocarcinoma

This study is evaluating an experimental drug called autogene cevumeran in patients with pancreatic ductal adenocarcinoma that has been resected (surgically removed). The goal is to find out whether combining these newer therapies (atezolizumab and autogene cevumeran) with standard chemotherapy is safe and more effective at reducing the risk of cancer returning compared to chemotherapy alone.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/​11 Mutations or PRKC Fusions

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 Tablet and Food Effect Pharmacokinetic (PK) Substudy will assess the PK profile of IDE196 tablet and evaluate the effects of food on the PK profile of IDE196 tablet Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.

This study may be appropriate for those with: Metastatic Cancer

Safety and Effectiveness of PYX-201 in Solid Tumors

This study is testing a new drug called PYX-201 in adults with advanced solid tumors that have not responded to usual treatments or for whom there are no suitable treatment options. The goal is to find out what dose of the drug is safe and can be tolerated well. Researchers will monitor participants to see how their bodies react to the drug, including any side effects and how the drug moves through their system. Participants must be adults with certain cancers, such as breast, lung, or ovarian cancer, who meet health criteria like having normal kidney and liver function. The study aims to explore both the safety and preliminary effectiveness of PYX-201 over approximately 3 years. It is open-label, meaning all participants receive the drug, and no placebo is involved. Measurements will focus on potential toxicities and adverse events as well as biological markers from blood samples. Participants must not have severe infections or other active cancers. The research hopes to pave the way for further clinical development if results are promising.

This study may be appropriate for those with: Recurrent Cancer

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

The main purpose of this study is to measure the safety and effectiveness with ivonescimab/SMT112 in combination with chemotherapy drugs, i.e., FOLFOX (Oxaliplatin, Leucovorin and Fluorouracil) in the first-line treatment of metastatic colorectal cancer (mCRC) compared to bevacizumab in combination with chemotherapy drugs, i.e., FOLFOX (Oxaliplatin, Leucovorin and 5-Fluorouracil). Ivonescimab/SMT112 is considered investigational and has not been approved by the U.S. Food & Drug Administration/local Regulatory Authority for treatment or sale. Bevacizumab is a different approved drug sold under the brand name Avastin. FOLFOX is a standard chemotherapy regimen made up of the drugs folinic acid (leucovorin, FOL), fluorouracil (5-FU, F), and oxaliplatin (Eloxatin, OX).

This study may be appropriate for those with: Metastatic Cancer

Letrozole Study in Recurrent High Grade Gliomas

Patients will receive up to 20 mg of letrozole orally each day both before and after surgical resection. The primary endpoint of this study is the measurement of tumoral bioavailability of letrozole.

This study may be appropriate for those with: Recurrent Cancer

Study of JANX007 in Metastatic Castration-Resistant Prostate Cancer

This study is exploring a new treatment called JANX007 for adults with metastatic castration-resistant prostate cancer. It is a Phase 1 trial, which is the first time this drug is being tested in humans. The main goal is to check its safety and find out if it can be tolerated by patients. Scientists will also look at how the body processes the drug and its initial effectiveness in fighting cancer. Participants need to have a type of prostate cancer that didn't respond to other treatments including hormone therapy and chemotherapy. The study will not include people who have had an organ transplant or specific heart problems.

This study may be appropriate for those with: Metastatic Cancer

Bladder Preservation Immunoradiation

This Phase II study tests whether combining the immune drug pembrolizumab with radiation therapy can allow people with muscle invasive bladder cancer to keep their bladder after the tumor has already shrunk from pre-surgery chemotherapy. Eligible patients have an excellent clinical response after neoadjuvant chemotherapy and will receive daily photon radiation to the bladder Monday through Friday for up to about 4 weeks while also getting pembrolizumab through an IV every 3 weeks. Before joining, patients have had a TURBT (a bladder tumor biopsy/removal procedure) and staging scans. The study tracks how long patients keep their bladder without cancer returning, whether they later need bladder removal (salvage cystectomy), survival outcomes, side effects, and patient-reported symptoms. Blood, urine, and tissue samples will be stored for future research. After finishing treatment, participants are followed regularly for up to 5 years.

This study may be appropriate for those with: Newly Diagnosed Cancer

Dose Escalation/​Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 alone or with Pembrolizumab

This clinical trial is assessing a new treatment, called TEV-56278, which is being tested alone and in combination with another drug called Pembrolizumab. This trial focuses on individuals who have advanced solid tumors. These types of tumors might be resistant to standard treatments or have not responded well to them. This study, conducted by Teva Branded Pharmaceutical Products, aims to find a safe and effective dosage of TEV-56278. It hopes to determine whether it can effectively inhibit tumor growth when used on its own or together with Pembrolizumab. Participants will be observed for any side effects and to see how well the tumor responds to the treatment. The study duration includes being treated for up to one year and followed for up to another year, totaling a possible two years per participant. The trial is ongoing, offering treatment possibilities for those who meet specific inclusion criteria, including having previously received treatment for their tumor and having a life expectancy of at least 12 weeks.

This study may be appropriate for those with: Metastatic Cancer

Study on IOV-4001 for Advanced Melanoma and NSCLC

This study is the first-in-human study of IOV-4001, a genetically modified autologous tumor- infiltrating lymphocytes (TIL) product. IOV-4001 is expected to have antitumor activity through its capacity to directly target and kill tumor cells in a manner that is similar to non-genome-edited TIL, but with the potential for enhanced antitumor activity due to disruption of PDCD1, the gene for programmed cell death protein-1 (PD-1).

This study may be appropriate for those with: Metastatic Cancer

Higher Dose Radiation Therapy for Advanced Pancreatic Cancer Trial

This study is exploring if giving higher doses of radiation can help people with advanced pancreatic cancer live longer. Participants must have already undergone 4-6 months of chemotherapy and have stable disease without progression. There are two groups in the study. One group will receive standard treatment, which could include continuing chemotherapy, a normal dose of radiation, or observation. The other group will receive higher doses of radiation over a shorter period to see if it prolongs their survival. Patients will have regular follow-ups and will be checked through blood tests, imaging scans, and tissue biopsies. They are monitored over a period that includes every three-month checkups for two years and then yearly for another three years. This study aims to not only see if survival improves but examine side effects, quality of life, and any changes in disease progression.

This study may be appropriate for those with: Metastatic Cancer

Early Pelvic Floor Therapy Study

This is a small single group study of 28 women with invasive cervical cancer who will get pelvic external beam radiation as part of their treatment. About four weeks after finishing radiation, participants will begin pelvic floor physical therapy. The study will measure how many women have fecal incontinence three months after radiation using a standard patient survey (EORTC QLQ CX24). A survey score of 1 or higher will count as incontinence. The study will also look at urinary incontinence, sexual symptoms, overall quality of life, how well participants follow recommended dilator use, and changes in pelvic floor muscle function (measured with the Brink scale). Assessments will be done before therapy and at three months after radiation. The goal is to see how common bowel leakage is after pelvic radiation and whether early pelvic floor therapy can be studied further as a supportive care approach.

DLBCL GCB Treatment Study

This is a phase 2 randomized study for people with newly diagnosed germinal center B-cell (GCB) subtype diffuse large B-cell lymphoma (DLBCL). It compares two treatment combinations given with standard chemo (R-CHP): zilovertamab vedotin (MK-2140) plus R-CHP versus polatuzumab vedotin plus R-CHP. The main goal is to see which group has more people with a complete response to treatment at the end of therapy, as measured by imaging reviewed independently. The study also follows participants for progression-free survival, overall survival, event-free survival, how long responses last, side effects, and quality of life measures. People must have PET-positive disease, no prior DLBCL treatment, and certain infections must be controlled to join. Some people are not eligible due to other lymphoma types, serious heart issues, active infections, significant nerve problems, recent other cancers, or recent transplants.

This study may be appropriate for those with: Recurrent Cancer

Amivantamab Versus Cetuximab in cSCC

This study is testing a new treatment approach for people with cutaneous squamous cell skin cancer that has come back or spread and who have weakened immune systems. Participants are placed into one of two groups. One group gets amivantamab given under the skin together with hyaluronidase to help the drug stay in the body longer. The other group gets cetuximab given into a vein. Treatment is given in 28-day cycles for up to about 24 cycles unless the cancer gets worse or side effects are too severe. Doctors will check safety, how well the cancer responds, and how long people live without cancer growth. Blood tests and scans will be done throughout treatment, and some patients will be followed afterward for years. The study also collects samples for future research.

This study may be appropriate for those with: Metastatic Cancer

Self Collection HPV Screening Study

This study tests whether people who collect their own vaginal sample for HPV testing get results that are as accurate as samples collected by a clinician during a pelvic exam. Adults 25 and older who were referred for colposcopy because of an abnormal cervical screening test will first collect a vaginal sample themselves, then have a clinician collect a cervical sample and undergo standard colposcopy with biopsy or other procedures if needed. Lab results are compared to see how well self-collection detects high-risk HPV and signs of cervical precancer or cancer. The study also asks participants about ease of use, comfort, and preferences for self-collection. Results will help guide use of self-collection for cervical cancer screening and possible regulatory decisions.

Study of PF-07934040 for Advanced Tumors with KRAS Gene Mutations

This clinical study is testing a new cancer medicine called PF-07934040. The study focuses on people with advanced solid tumors, which are cancers that don't go away or stay away after treatment. These tumors have a specific genetic mutation in the KRAS gene, which can make cancer cells grow quickly. The study includes people with types of cancer such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). The study is in Phase 1, meaning it's looking at how safe the medicine is and what effects it has. Researchers also want to find the best dose to give to patients. The medicine can be taken alone or with other cancer treatments. Participants will take PF-07934040 as a pill twice a day in cycles of either 21 or 28 days. Those who are also getting other treatments will have those given by IV at the clinic. The study will last up to four years, with participants visiting the clinic 1 to 4 times every cycle. They can continue the treatment as long as it helps control their cancer. After stopping the medicine (usually around two years), they will be followed for two more years to check on their health. To join the study, participants must have a KRAS gene mutation and show that their cancer has not responded to standard treatments. They must also have a good level of daily functioning and at least one measurable tumor that has not been treated with radiation. There are also specific criteria for different cancer types, such as the number of previous treatments. People cannot join if they have certain health problems, like lung diseases that need steroids, immune system issues, or severe nerve damage. They also can't participate if they've had major surgery or radiation therapy recently, or if they have allergies to the study treatments. The study aims to learn if PF-07934040 is safe and effective in treating these advanced cancers. It will measure safety through any side effects and lab test changes. It will also look at how many participants respond to the treatment, how long it takes for the medicine to reach its peak in the body, and how long it stays there.

This study may be appropriate for those with: Relapsed / Refractory Cancer

TAPUR Study: FDA Approved Drugs Targeting Tumor Gene Abnormalities

The TAPUR Study is focused on understanding how FDA-approved drugs that target specific abnormalities in tumor genes work for patients with advanced cancers. These include solid tumors, multiple myeloma, and non-Hodgkin lymphoma that have a detectable genetic feature that can potentially be treated with these medicines. The study evaluates participants' responses, safety of treatments, survival rates, and helps to form ideas for new clinical trials based on real-world usage of these therapies. Anyone aged 12 or older with certain advanced cancers whose condition can be measured and who meets other criteria may participate. However, those with certain conditions like primary brain tumors or unmeasurable disease may not be eligible.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Study of Isatuximab, Carfilzomib, and Dexamethasone for Multiple Myeloma

This clinical study focuses on adults with relapsed or refractory multiple myeloma who have had 1 to 3 previous treatments that did not work. The study tests a combination of drugs: isatuximab, carfilzomib, and dexamethasone. The main goal is to see how well this treatment works in fighting the cancer and how the patients respond to it, both physically and emotionally. Participants go through a screening period, followed by up to a year of treatment. They will visit the study location periodically for evaluations. The study measures various outcomes, including overall response rate and possible side effects like infusion reactions. It's important that participants are able to commit to the protocol and fit specific medical criteria while avoiding recent treatments or conditions that might interfere with the study.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Vorasidenib with Temozolomide Trial

This Phase 3 clinical trial tests whether adding vorasidenib to the usual post‑radiation chemotherapy (temozolomide) helps people with newly diagnosed IDH‑mutant grade 3 astrocytoma. Patients are randomly assigned to one of two groups: both get standard radiation followed by temozolomide tablets, and one group also gets vorasidenib tablets while the other gets a placebo. Treatment cycles are 28 days, with the study drug taken daily and temozolomide given on days 1-5 of each cycle, for up to 12 months if the disease does not get worse and side effects are acceptable. Doctors will check tumor status with regular MRI scans and blood tests. The main goal is to see whether adding vorasidenib delays tumor growth (progression‑free survival). The study also looks at safety, overall survival, tumor response, time to next treatment, seizure control, and quality of life. After finishing study drugs, participants are followed for several years to monitor long‑term outcomes.

This study may be appropriate for those with: Newly Diagnosed Cancer

A Multicenter Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated and T474 Gatekeeper Mutant CLL/SLL

This is a phase II research study being conducted at multiple locations. It is designed to test the combination of obinutuzumab and LP‑168 in two groups of people with CLL/SLL: those who have been treated before, and those whose disease has a specific genetic change that makes it harder to treat with standard therapies.Participants will take LP‑168 once a day, starting on the first day of treatment, for up to 12 treatment cycles. About two weeks after finishing the first six cycles, their progress will be checked using blood tests, imaging scans, and a bone marrow sample. After this check‑in, participants will continue taking LP‑168 and will also begin receiving obinutuzumab. Obinutuzumab will be given over six cycles, starting in cycle 7, on several scheduled days early on and then once per cycle through cycle 12. Everyone will receive at least 12 cycles of treatment. At the end of cycle 12, participants will be evaluated again to see how well the treatment worked. This will include blood tests, scans if needed, and examination of blood and bone marrow samples to look for any remaining signs of disease. Participants whose disease is no longer detectable at that point may choose to stop treatment. Those who still have signs of disease will continue taking LP‑168 and will be followed every six months. Additional testing may be done later, and treatment can be stopped if no disease is detected at that time.

This study may be appropriate for those with: Recurrent Cancer

At-Home HPV Screening in the Community

Adults with a cervix can choose to self-test for HPV at a mobile clinic. Education and follow-up support are provided to help prevent cervical cancer.

Beat AML Biomarker Treatment Trial

This study is a master protocol that screens people with acute myeloid leukemia (AML) using rapid lab and genomic testing. Based on the test results, each person is placed into one of several smaller treatment studies that test targeted, investigational therapies or drug combinations. The goal is to complete testing and assign patients to a matched treatment within 7 days, and then follow treatment responses and safety over time. The trial includes groups for newly diagnosed patients, relapsed or refractory patients, and a marker-negative group for those who don't match a specific marker. Some sub-studies focus on older adults or patients who cannot or choose not to get intensive chemotherapy. Follow-up can continue for years to track responses and changes in disease over time.

This study may be appropriate for those with: Newly Diagnosed Cancer

Phase 2 Study of ACR-368 in Endometrial Cancer

This Phase 2 study tests ACR-368 in people with high-grade endometrial cancer. Participants are placed into one of three groups. Arms 1 and 2 use a lab test called OncoSignature to predict sensitivity to ACR-368: Arm 1 (OncoSignature Positive) receives ACR-368 alone; Arm 2 (OncoSignature Negative) receives ACR-368 plus ultra-low dose gemcitabine (ULDG). Arm 3 (no OncoSignature testing) also receives ACR-368 with ULDG; EU sites enroll only to Arm 3. Treatment continues until the cancer gets worse, side effects become unacceptable, or the person stops. The main goal is to measure tumor response by CT or MRI every 8 weeks for up to 2 years. Safety, some drug levels in blood, overall survival, time without cancer growth, and duration of any response are also tracked. Key eligibility includes prior platinum chemotherapy and prior anti-PD-(L)1 therapy, measurable disease, and adequate overall health. Certain conditions like uncontrolled viral infections, serious heart disease, recent major surgery or recent cancer treatment, symptomatic brain metastases on high-dose steroids, bowel obstruction, or prior CHK1 inhibitor use will exclude people from joining.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

This study may be appropriate for those with: Newly Diagnosed Cancer

Testing LY3962673 in KRAS G12D-Mutant Solid Tumors

This study is examining a new drug, LY3962673, which aims to treat certain types of advanced cancer that have a specific mutation known as KRAS G12D. These cancers include pancreatic, lung, and colorectal cancers. The study is testing how safe LY3962673 is when used alone and in combination with other chemotherapy drugs, as well as how well it works in reducing tumor size. It will last about five years, and participants will undergo various assessments to track their response to the treatment. The study hopes to determine both the best way to use the drug and its effectiveness over time. Participants who previously had treatments that didn't fully work for these specific cancers might qualify.

This study may be appropriate for those with: Metastatic Cancer

Investigating NBTXR3 and Radiation for Head and Neck Cancer

This study is testing a treatment called NBTXR3 to see how well it works when combined with radiation therapy, compared to just using radiation therapy with or without a drug called cetuximab. The research is focused on elderly patients who have advanced head and neck squamous cell cancer but cannot undergo platinum-based chemotherapy. Participants will be randomly assigned to two groups; one will receive NBTXR3 with radiation therapy, and the other will receive radiation therapy alone or with cetuximab as chosen by their doctor. The goal is to track how long patients live without their cancer getting worse and overall survival, among other measures. The treatment happens over 7 weeks, with a series of follow-up visits planned afterward.

This study may be appropriate for those with: Metastatic Cancer

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

This clinical trial examines the effectiveness and safety of a new drug, UGN-104, for patients with low-grade upper tract urothelial cancer. During the study, UGN-104 is administered directly into the upper urinary tract once a week for six weeks. Patients who show no signs of cancer after these treatments will have follow-up visits and may continue receiving monthly doses as a maintenance treatment plan for up to one year. These maintenance visits help ensure that the cancer does not return. The study involves regular check-ups every three months and lasts up to 15 months. Participants must have been diagnosed with this type of cancer and should not have received certain other treatments or have specific health conditions.

This study may be appropriate for those with: Recurrent Cancer

Beat AML Biomarker Treatment Trial

This study is a master protocol that screens people with acute myeloid leukemia (AML) using rapid lab and genomic testing. Based on the test results, each person is placed into one of several smaller treatment studies that test targeted, investigational therapies or drug combinations. The goal is to complete testing and assign patients to a matched treatment within 7 days, and then follow treatment responses and safety over time. The trial includes groups for newly diagnosed patients, relapsed or refractory patients, and a marker-negative group for those who don't match a specific marker. Some sub-studies focus on older adults or patients who cannot or choose not to get intensive chemotherapy. Follow-up can continue for years to track responses and changes in disease over time.

This study may be appropriate for those with: Newly Diagnosed Cancer

Family Genetic Communication Study

This study tests two ways of letting close family members know about inherited genetic changes found in people newly diagnosed with colorectal cancer. First, patients (called probands) get blood testing for inherited cancer genes. If a harmful inherited change is found, the patient and their eligible first-degree relatives are put into one of two groups. In the usual approach, the patient tells relatives about the test result (proband-mediated). In the other approach, a healthcare team member contacts relatives directly to offer testing and information (provider-mediated). The main goal is to see which method leads to more relatives getting genetic testing within 6 months. The study also looks at whether relatives who test positive take prevention steps within a year, whether testing differs by patient subgroups (such as age, race, or rural vs. urban), the range of inherited variants found, and patient disease-free survival over 3 years. Probands are followed up for up to 3 years; relatives are followed for up to 1 year. Materials and counseling are provided in English or Spanish.

Study of BNT327 and Chemotherapy for Lung Cancer Treatment

This study is exploring a new drug, BNT327, combined with chemotherapy to treat people with advanced non-small cell lung cancer (NSCLC). The study has two parts (Phase 2 and Phase 3) that compare different doses of BNT327 to find the best option. Participants are split into groups based on the type of lung cancer they have. The study will look at how safe the treatments are and if they work better than current options. It's a global trial where researchers want to see if using BNT327 can improve survival rates and reduce tumor size better than just using chemotherapy alone. It's ongoing, so more participants who fit the requirements are being recruited.

This study may be appropriate for those with: Metastatic Cancer

Testing Abemaciclib with 5-Fluorouracil for Metastatic Colorectal Cancer

This clinical trial is investigating how well two drugs, Abemaciclib and 5-Fluorouracil (5-FU), work together in treating people with colorectal cancer that has spread to other parts of the body and hasn't responded to other treatments. The study aims to discover the safest dose of the drug combination that patients can handle without severe side effects. Participants will take Abemaciclib by mouth twice daily, and receive 5-FU through a vein on specific days during each 28-day cycle. Throughout the study, various samples will be collected to track the effectiveness and side effects of the treatment. After finishing the treatment cycles, participants will be monitored every three months for follow-up. Researchers hope this combination will provide a new option for those with this difficult-to-treat cancer type.

This study may be appropriate for those with: Metastatic Cancer

Testing Radiation Plus Immunotherapy for Metastatic Renal Cell Cancer

This clinical trial is testing whether adding a special type of radiation therapy called stereotactic ablative radiation therapy (SABR) to the usual treatment of immunotherapy can help patients with renal cell cancer that is metastatic, meaning it has spread to other parts, or cannot be surgically removed. Patients are divided into two groups. One group receives only immunotherapy, while the other group gets both SABR and immunotherapy. The hope is that using both SABR and immunotherapy could shrink tumors or stop them from growing. By doing this, doctors aim to see if fewer surgeries are needed and if the time without cancer worsening can be extended. The study will also look at safety and possible side effects such as immune system reactions.

This study may be appropriate for those with: Metastatic Cancer

One Stop Cervical Screening System

This study will test a new, low‑cost system that uses urine spectroscopy and artificial intelligence (AI) on cervical photos to screen and triage women for cervical cancer in Zimbabwe. The project has two parts. In Part 1 (about 2 years) researchers will collect urine and self‑collected vaginal samples from about 1,100 women to improve the urine spectroscopy AI and compare its results to a standard HPV test. They will also collect more cervical images to improve the image‑reading AI and teach it to recognize the transformation zone type. In Part 2 (about 3 years) around 2,100 women will be screened with the AI urine test and a validated HPV test. Women who test positive will have colposcopy, cervical imaging, and biopsy if needed. The study will measure how well the AI urine test and the AI image triage detect histology‑confirmed CIN2+ (high grade precancer or cancer) compared with standard tests, and will check how well AI determines the transformation zone type. The team will also compare costs versus current local practice. Most participants will have one screening visit. HPV‑positive women will return for colposcopy, biopsy, and treatment if required. The study is carried out by IARC with partners in Zimbabwe and other institutions.

Effect of a Virtual Reality Cognitive Training Intervention for Brain Cancer Survivors

You will either be assigned to a group that uses the virtual reality training system or a group that will complete paper word search puzzles. At the start of the study all participants will be asked to complete three short cognitive tests to check your current memory and thinking skills. You will take the same tests again at the end of the study to see if anything has changed or improved. You will receive a schedule based on your start and end dates that explains which days you will need to complete the study-related tasks. You will complete the tasks at home for 4 weeks, 6 days a week. It will start at 15 minutes a day in week one and increase by 5 minutes each week, ending at 30 minutes a day in week four. You will receive either a VR headset and hand controllers for use with VR-CRT (and portable WI-FI hotspot if you do not have WI-FI at home) or a notebook for use with paper word-search puzzles (WSP). The research study will provide the technology to you free of charge, but with a technology sign-out consent to confirm your agreement to return the VR and WI-FI equipment once the study is completed. If you are in the VR group, you will be trained on how to use the equipment and how to connect the VR equipment to WIFI. Off-the-shelf VR equipment (Meta Quest 3/128 GB with WIFI) will be used.

Sac TMT Maintenance in Ovarian Cancer

This late-stage (Phase 3) study is testing a new maintenance option for people with newly diagnosed advanced ovarian cancer whose tumors are HRD-negative. Participants will have already had surgery and first-line platinum-based chemotherapy and shown no disease growth or some response. The study compares sacituzumab tirumotecan (an antibody-drug therapy) given as maintenance, with or without the targeted drug bevacizumab, to the usual standard care (which may include observation or bevacizumab maintenance). The main goal is to find out if the study treatment keeps cancer from getting worse for longer. Researchers will also track overall survival, later disease progression after new treatments, safety and side effects, and quality of life measures using standard questionnaires. Participants will have regular clinic visits for treatment, scans, and assessments during the treatment and for long-term follow-up. The full study follow-up can last several years to measure how long benefits and side effects last.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study of IMPT-314 in R/​R Aggressive B-cell NHL

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Two cohorts of participants will be enrolled: 1) CAR T naïve and 2) CAR T experienced. Up to approximately 60 patients (15 per dose level per cohort) will be enrolled in dose finding Phase 1 part of the study, which will determine the recommended phase 2 dose. Phase 2 will enroll up to approximately 40 additional participants (20 per cohort) to evaluate further the safety and efficacy of IMPT-314. IMPT-314 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a conditioning chemotherapy regimen consisting of fludarabine and cyclophosphamide, administered over 3 days. Individual participants will remain in the active post-treatment period for approximately 2 years. Participants will continue in long-term follow-up for 15 years from treatment.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Comparing Effectiveness of Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

This phase II study evaluates the effectiveness of mosunetuzumab versus rituximab, the standard treatment, in extending survival for patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Both mosunetuzumab and rituximab are monoclonal antibodies targeting the CD20 protein on B cells and certain cancer cells, potentially enhancing the immune system's ability to destroy cancer cells. The trial aims to determine if mosunetuzumab offers a superior survival benefit compared to rituximab for individuals with NLPHL.

This study may be appropriate for those with: Relapsed / Refractory Cancer

DB 1324 in Gastrointestinal Cancer

This first-in-human study will test DB-1324 in people with advanced or metastatic gastrointestinal (GI) cancers. The study has two main phases. Phase 1 uses dose escalation and expansion steps to find a safe and tolerable dose and to learn how the drug behaves in the body. Phase 2 will further check safety and look for signs the drug can help certain GI cancers. Participants will get DB-1324 regularly until their disease worsens, they have unacceptable side effects, they choose to stop, or another reason for stopping occurs. Researchers will watch for side effects, serious adverse events, and dose-limiting toxicities to find the maximum tolerated dose and recommended doses for later studies. The study will also measure tumor response, how long any responses last, time until progression, and drug levels in the blood. Participants will need to provide tumor tissue or allow a biopsy for testing biomarkers such as CDH17.

This study may be appropriate for those with: Metastatic Cancer

Testing New Drug Combo for Treating Acute Myeloid Leukemia

This clinical trial is exploring a new treatment plan for patients with newly diagnosed acute myeloid leukemia (AML). The study is testing the effectiveness and safety of combining three anti-cancer drugs: iadademstat, venetoclax, and azacitidine. These drugs work together to stop the cancer cells from growing and spreading. The main aim is to find the best dose and check if this combination approach could help improve health outcomes for these patients. Participants will first undergo an initial treatment phase, where they take these medications daily for certain periods, repeated every month for three months. If no complications arise, they continue the treatment for up to two years. The study also looks at how patients' bodies respond to the treatment over time. Participants need to be newly diagnosed, adults, in good general health, and able to swallow pills. Certain health conditions and previous treatments could disqualify someone from joining the study. During and after treatment, regular check-ups will monitor patients' responses and any side effects. This trial could point the way forward in finding a more effective treatment for AML.

This study may be appropriate for those with: Recurrent Cancer

Pasritamig for Advanced Prostate Cancer

This is a late‑stage phase 3 study testing pasritamig (JNJ‑78278343), a medicine that redirects a person's T cells to target a prostate cancer protein, in people with metastatic castration‑resistant prostate cancer (mCRPC) whose disease has progressed after standard treatments. Participants are randomly assigned to receive pasritamig plus best supportive care or placebo plus best supportive care. The main goal is to compare overall survival between the two groups. Other goals include measuring time to disease progression by imaging, time to symptom or pain worsening, time to events in the bones, lab changes, and side effects. Participants must be on ongoing hormone suppression and have already received available life‑prolonging therapies appropriate for them. The study follows participants for up to about 2 years and 8 months to assess outcomes.

This study may be appropriate for those with: Metastatic Cancer

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

This is a Phase II trial with an anticipated total of 37 patients enrolled. Treatment will consist of 5 fractions of lattice radiation therapy delivered every other day. The primary endpoints will include the efficacy of lattice therapy as evaluated by Overall Response Rate to the treatement at 60 days (2 months) post-treatment, and safety.

This study may be appropriate for those with: Metastatic Cancer

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

This study aims to determine whether rectal cancer's response to treatment is the same when patients receive chemotherapy alone before limited surgery versus when they receive both chemotherapy and radiation therapy before limited surgery, and if omitting radiation therapy improves quality of life.

This study may be appropriate for those with: Newly Diagnosed Cancer

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer

This phase III trial evaluates the effectiveness of pembrolizumab versus observation in treating patients with early-stage triple-negative breast cancer who have reached a pathologic complete response following preoperative chemotherapy combined with pembrolizumab. Pembrolizumab, a type of immunotherapy using monoclonal antibodies, aims to boost the immune system's ability to combat cancer and may block tumor cells from multiplying and spreading. The study aims to ascertain whether observation alone offers the same risk of cancer recurrence as continued pembrolizumab treatment in these patients after surgery.

This study may be appropriate for those with: Newly Diagnosed Cancer

A Study of DB-1311 in Advanced/​Metastatic Solid Tumors

This Phase 1/2a trial aims to assess the safety and tolerability of DB-1311 in patients with advanced solid tumors through dose-escalation and dose-expansion studies.

This study may be appropriate for those with: Metastatic Cancer

Study of ZE50-0134 for Chronic Lymphocytic Leukemia and Lymphomas

This clinical trial is mainly for adults who have a type of blood cancer known as Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), as well as some other related low-grade lymphomas. The study aims to test a new treatment called ZE50-0134. It's designed to see how safe the medicine is, how it moves through the body, and how well it works against these illnesses. In the first part of the study, doctors will try different doses to find the highest amount patients can handle safely. In the second part, they will explore how effective this dose is and confirm safety with a focus on long-term usage. Patients will participate in multiple cycles of treatment, each cycle lasting four weeks, up to a total of 24 cycles, but detailed visits depend on patient grouping and specific needs. This trial is open label, meaning patients will know they are receiving ZE50-0134. Participants must be at least 18 years old and have already tried some other treatments unsuccessfully. They shouldn't have certain health issues like active infection, severe heart problems, or recent surgery. Pregnancy testing is required for women of childbearing potential before starting the drug.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Contact UCCC CTO for Study Activation

Specific study details/protocols can be provided upon request

Exploring Mindfulness Apps for Breast Cancer Survivors

This study examines two digital mindfulness programs designed to help younger women who survived breast cancer. Participants are randomized into two groups: one using a live, instructor-led program over the internet, called MAPs LO, delivered via Zoom, and the other using a self-paced app-based version, called MAPs App. The research aims to determine which approach best improves the mental health of those who completed their primary cancer treatment and now have depression symptoms. Another goal is to identify specific patient traits or psychological conditions that predict which digital format works better for whom. The study will also assess the cost-effectiveness of these different interventions, which is essential information for insurance, healthcare providers, and patients. Participants need to have completed initial treatments at least six months ago and show depressive symptoms but should not be engaged in similar ongoing trials.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study of RAS Inhibitors in GI Tumors

This clinical study is investigating new drugs called RAS inhibitors for treating gastrointestinal cancers, focusing mainly on colorectal and pancreatic cancers. The goal is to see if these drugs are safe, how well they are tolerated by patients, and if they show any early signs of fighting the cancer. Researchers are combining these RAS inhibitors with standard cancer treatments or other new drugs to find the most effective therapy. The study has three main parts, each testing a different combination of drugs: 1. **Part A**: This part looks at RMC-6236 combined with 5-fluorouracil-based treatments in patients who have not received prior treatment for their unresectable or metastatic colorectal cancer or metastatic pancreatic cancer. 2. **Part B**: In this segment, RMC-6236 is paired with cetuximab, and sometimes with mFOLFOX6, for patients with unresectable or metastatic colorectal cancer or those who have either previously treated or newly diagnosed metastatic pancreatic cancer. 3. **Part C**: This section tests RMC-6236 combined with gemcitabine and nab-paclitaxel in patients who have newly diagnosed metastatic pancreatic cancer. Each part of the study is open-label, meaning that both the doctors and the patients know which treatments are being given. The study consists of two phases: Dose Exploration to find the right dose levels and Dose Expansion to further evaluate the selected doses. To join the study, participants must be adults with specific types of cancer and good overall health. They should not have had major surgery 28 days before starting the study, and cannot have certain health issues like primary CNS tumors or GI problems that might affect the drug's absorption. The main outcomes of the study include monitoring for adverse events, understanding how the drug moves through the body, and measuring how well the drug works against the cancer. These measurements will include looking at how long and how well patients respond to the treatment, how long they live without the cancer getting worse, and their overall survival time. The study is currently recruiting participants and holds promise for finding more effective treatments for GI cancers involving mutations in the RAS gene.

This study may be appropriate for those with: Metastatic Cancer

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

This phase II trial evaluates the effectiveness of administering durvalumab alongside the standard chemotherapy regimen of gemcitabine and cisplatin prior to surgery in patients with high-risk, surgically removable liver cancer (cholangiocarcinoma). Durvalumab, a monoclonal antibody, may block tumor growth and spread. Gemcitabine and cisplatin, chemotherapy drugs, work to halt tumor cell proliferation by various mechanisms. The combination of durvalumab with these chemotherapies before surgery aims to shrink the tumor and minimize the removal of healthy tissue in patients with high-risk resectable cholangiocarcinoma.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study of GIM-531 for Advanced Solid Tumors

This study examines the safety and effectiveness of a new oral drug, GIM-531, specifically aimed at treating advanced solid tumors. It's divided into two phases, with Phase 1 focusing on finding a safe dose and Phase 2 expanding to further assess its safety and initial anti-tumor activity. GIM-531 works by selectively inhibiting certain immune cells called regulatory T-cells, which may help control tumor growth. The study measures the frequency and intensity of side effects, dose limitations, and how well the drug works against tumors. Participants will be those whose cancer has worsened after other treatments and must meet specific health criteria.

This study may be appropriate for those with: Metastatic Cancer

Study on Teclistamab and Talquetamab for Treating Multiple Myeloma

This study is testing two new treatment combinations for people with newly diagnosed multiple myeloma who can't have a stem cell transplant right away. It explores if mixing new drugs, teclistamab and talquetamab, with daratumumab and lenalidomide works better than the usual treatment that includes daratumumab, lenalidomide, and dexamethasone. The main goal is to see how long participants live without their disease getting worse. Researchers will also monitor how many people have no signs of cancer after a year. People who join this study should not have been treated for multiple myeloma before (except for some steroids) and must meet health criteria like not planning pregnancies. It excludes people with recent severe health issues or allergies to the drugs used. The study could last up to nine years for each participant.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study on New Treatment for Recurrent Ovarian Cancer

This study is looking at how effective and safe a new drug called sacituzumab tirumotecan, alone or with another drug called bevacizumab, is compared to the usual treatments for people whose ovarian cancer has come back after responding well to platinum-based chemotherapy. The study hopes to find out if patients can live longer without their cancer getting worse with this new treatment and if it's tolerable and safe. They will measure how patients respond to the treatment and monitor any side effects. The trial is in its third phase and will take place over four years.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Life After Skin Cancer Reconstruction

Patients answer questionnaires before and after reconstruction surgery for up to a year. The study helps doctors understand emotional recovery after skin cancer surgery.

Testing Venetoclax for Relapsed Hairy Cell Leukemia

This study is investigating the effectiveness of the drug venetoclax in patients whose hairy cell leukemia has returned after initial treatment. Venetoclax works by blocking a protein necessary for cancer cell survival, potentially reducing cancer growth. Participants will take venetoclax daily in cycles, and their response will be monitored through medical tests, including blood samples and imaging scans. The study aims to measure the overall response rate, complete remission, and any side effects. Eligible participants are those who have not had prior venetoclax treatment and meet specific health criteria. People with certain conditions or allergies should not participate. The study will follow participants for 30 days after their last medication dose to assess outcomes.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Amivantamab added to carboplatin and pembrolizumab vs standard platinum regimens in treatment‑naive R/M HNSCC

This study is to see how well a treatment that includes amivantamab, pembrolizumab and carboplatin works compared to a different treatment that includes 5-FU, pembrolizumab and platinum (carboplatin or cisplatin) therapy. 5-FU, pembrolizumab and platinum (carboplatin or cisplatin) are already used together to treat recurrent/metastatic head and neck squamous cell carcinoma.

This study may be appropriate for those with: Metastatic Cancer

Panitumumab for KRAS Wild Type Pancreas

This is a phase III randomized trial for adults with pancreatic ductal adenocarcinoma that cannot be removed by surgery or that has spread, whose tumors are KRAS wild type and BRAF V600E wild type by tissue testing. Participants are assigned to one of two groups. One group receives standard second line chemotherapy (one of several standard regimens) alone. The other group receives the same chemotherapy plus panitumumab, an antibody that targets EGFR on tumor cells. Treatment is given in 28 day cycles, typically with drug infusions on days 1 and 15, and continues until the cancer progresses or side effects are unacceptable. The main goal is to see whether adding panitumumab improves overall survival. The study also compares tumor response, progression free survival, side effects, and quality of life. Blood and tumor samples may be collected and stored for future research. Participants are followed for up to three years after randomization.

This study may be appropriate for those with: Metastatic Cancer

A Study of NX-5948 in Adults With Relapsed/​Refractory B-cell Malignancies

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies

This study may be appropriate for those with: Relapsed / Refractory Cancer

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with metastatic kidney cancer. Patients will receive 1 of the following 4 treatment options: Nivolumab 240 mg IV 1 q 2 weeks, Nivolumab 480 mg IV 1 q 4 weeks, Pembrolizumab 200 mg IV 1 q 3 weeks and Axitinib 5 mg oral Daily BID, OR Avelumab 10 mg/kg IV 1 q 2 weeks and Axitinib 5 mg oral Daily BID. Those in Arm 2 will also undergo a radical or partial nephrectomy. Efficacy will be measured by determining Overall Survival.

This study may be appropriate for those with: Newly Diagnosed Cancer

First Test of Cancer Drug YL217 for Patients with Advanced olid Tumors

This clinical study is the first time YL217 will be tested in humans. YL217 is a special kind of drug designed to help people with advanced solid tumors. The goal is to see how safe this drug is, how well the body tolerates it, and if it can help treat the cancer. Doctors will monitor the side effects and try to find the best dose that can be given safely. The study is specifically for adults with certain advanced cancers who have good overall health but have failed other treatments.

This study may be appropriate for those with: Metastatic Cancer

Study on New Bladder Cancer Treatment Options

The study is testing a new approach to treat high-grade, non-muscle invasive bladder cancer that doesn't respond to BCG treatment. The trial will look at a medication called nadofaragene firadenovec, which is inserted directly into the bladder. Researchers will compare this treatment alone and in combination with chemotherapy or immunotherapy. They want to see if these treatments can achieve a complete response, meaning the cancer does not return within 6 months of treatment. The study checks how long this effect lasts and whether the disease progresses to a more severe form. Participants must have a specific type of bladder cancer and not have serious disease elsewhere to join. They should not have tried similar experimental treatments before. The goal is to find out if these treatments can offer a new solution for patients whose current options are limited.

This study may be appropriate for those with: Metastatic Cancer

Radiation With Cetuximab or Chemotherapy

This phase 3 trial compares two treatments given with high-precision radiation therapy (IMRT) for people with advanced head and neck cancer who cannot take cisplatin. Patients are randomly placed into one of two groups. One group gets weekly cetuximab (a drug that targets the EGFR protein on some cancer cells) together with 35 daily radiation treatments over about 7 weeks. The other group gets weekly carboplatin and paclitaxel chemotherapy together with the same radiation schedule. Patients have scans and blood tests during the study and are followed after treatment at 30 days, then at 4, 6, 12, 18, 24, 30, and 36 months and then yearly. The main goal is to compare progression-free survival between the two groups. Secondary goals include comparing overall survival, side effects, where the cancer returns if it does, and changes in eating and speaking function.

This study may be appropriate for those with: Metastatic Cancer